DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • July 16th, 2021
Development Details Content Provisionally called [Title] DevelopmentSpecifications Content Genre e.g. Drama, Comedy, Documentary,Children Number & Duration ofEpisodes [Number & Duration] Delivery Date Platform [Platform] Platform Channel [channel] Intended Distribution (if known) e.g. broadcast timeslot, onlinerelease plan Key Personnel Commissioning Editor Producer Director Writer/s Researcher DevelopmentDeliverables [list deliverables - e.g. Script, character notes, treatment, storylines,short pilot video, series bible] Qualifications or Restrictions on Producer’s Rights Scriptwriter’s right of reversion (if any) anddate: Option Expiry Date: Other Rights/ Restrictions (if any): Previous Development Funding already contracted and advanced (delete if N/A) NZ On Air Funding $[NZOA previous] Platform Funding Other Funding Total previous funding $[Total previous] Development Budget & Funding Details Budgeted Costs Budgeted Cash Costs $[Total] Budg
DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • May 30th, 2013 • Hampshire
E The Council and the [Developer] [Registered Provider] agree that the Capital Grant is to be made in accordance with the Commission Decision.
FOURTH MODIFICATION TO UCFRF/WINTER SPRINGS INCUBATOR ECONOMIC DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • September 14th, 2020
DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • May 7th, 2019 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Development Funding Agreement (“Agreement”), made effective as of February 28, 2019 (the “Effective Date”), is by and between Apellis Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 6400 Westwind Way, Suite A, Crestwood, KY 40014, USA (“Apellis”), and SFJ Pharmaceuticals XI, L.P. (“SFJ”), an SFJ Pharmaceuticals Group company and limited partnership organized and existing under the laws of Delaware, having its principal place of business at 5000 Hopyard Road, Suite 330, Pleasanton, CA 94588, US (each, a “Party” and collectively, the “Parties”).
AMENDMENT TO DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • July 31st, 2019 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Development Funding Agreement (“Amendment”), made effective as of June 7, 2019 (the “Amendment Date”), entered into by and between Apellis Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 6400 Westwind Way, Suite A, Crestwood, KY 40014, USA (“Apellis”), and SFJ Pharmaceuticals XI, L.P. (“SFJ”), an SFJ Pharmaceuticals® company and limited partnership organized and existing under the laws of Delaware, having its principal place of business at 5000 Hopyard Road, Suite 330, Pleasanton, CA 94588, USA, amends that certain Development Funding Agreement dated as of February 28, 2019 (the “Agreement”), by and between Apellis and SFJ.
AMENDMENT TO DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • May 18th, 2021 • Stealth BioTherapeutics Corp • Pharmaceutical preparations
This Amendment to Development Funding Agreement (this “Amendment”), dated as of May 17, 2021 (the “Amendment Effective Date”) is by and between Stealth Bio Therapeutics Corp, a Cayman Islands exempted company with registered number 165223, (“Stealth”) and Morningside Venture (I) Investments Limited (“Morningside”).
Development Funding Agreement by and between Opthea Limited and Ocelot SPV LPDevelopment Funding Agreement • September 29th, 2022 • Opthea LTD • Biological products, (no disgnostic substances) • New York
This Development Funding Agreement (“Agreement”), dated August 12, 2022 (the “Effective Date”), is by and between Opthea Limited ACN 006 340 567, a company incorporated under the laws of Victoria, Australia (“Opthea”), and Ocelot SPV LP, a Delaware limited partnership (“Investor”). Each of Investor and Opthea may be referred to herein individually as a “Party” and collectively as the “Parties”.
DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • November 4th, 2020 • Stealth BioTherapeutics Corp • Pharmaceutical preparations • Delaware
This Development Funding Agreement (“Agreement”), made effective as of October 30, 2020 (the “Agreement Effective Date”), is by and between Stealth Bio Therapeutics Corp, a Cayman Islands exempted company with registered number 165223, (“Stealth”), Morningside Venture (I) Investments Limited (“Morningside”) and the investors listed on Schedule 1 attached to this Agreement (together with Morningside, the “Investors”). The parties hereto may each be referred to herein individually as a “Party” and collectively, the “Parties”.
DEVELOPMENT FUNDING AGREEMENTDevelopment Funding Agreement • November 14th, 2006 • Akorn Inc • Pharmaceutical preparations • New York
This Development Funding Agreement (this “Agreement”) is entered into on November 7, 2006 (“Effective Date”) between AKORN, INC., a Louisiana corporation having a principal place of business at 2500 Millbrook Drive, Buffalo Grove, Illinois 60089-4694, United States of America (“AKORN”) and SERUM INSTITUTE of INDIA, LTD., a Company incorporated under the laws of India laws, having its principal place of business at S. No. 212/2, Off Soli Poonawalla Road, Hadapsar, Pune — 411 028, Maharashtra, INDIA, (“SII”) (each a “Party” and collectively, the “Parties”).
